Welcome To Spring Bank Pharmaceuticals

Latest News

- DECEMBER 26, 2019
Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program
HOPKINTON, Mass. , Dec. 26, 2019 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain can…
Read more

- DECEMBER 9, 2019
Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
HOPKINTON, Mass. , Dec. 09, 2019 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain can…
Read more

VIDEO

See the mechanism of action of inarigivir soproxil, our lead development candidate for the treatment of hepatitis B virus (HBV)

©2020 Spring Bank Pharmaceuticals. - Terms of Service, Privacy Policy, Disclaimer for Twitter , Disclaimer for LinkedIn